Drugs and FDA
FDA approves neladalkib for previously treated ALK-positive lung cancer
The FDA approved neladalkib for adults with advanced ALK-positive lung cancer after alectinib or at least two prior ALK inhibitors plus platinum-based chemotherapy.

The FDA granted accelerated approval on November 17, 2026, to neladalkib (Nelkarmi) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer previously treated with alectinib, or with at least two prior ALK inhibitors and platinum-based chemotherapy.
Approval was based on the ALKOVE-1 trial. Among 67 patients previously treated with alectinib, 49% responded, and 76% of responders had a response lasting at least 6 months. Among 155 patients treated with two or more prior ALK inhibitors and platinum-based chemotherapy, 32% responded, and 69% of responders had a response lasting at least 6 months. The FDA lists warnings for liver, kidney and eye toxicity, among other risks. An ongoing phase III trial is testing neladalkib as an initial treatment.


